Recent Years Show Booms for Oncotarget

The work just keeps rolling out due to the production of Oncotarget and its network of researchers. Over a span of just only 5 years, from 2011 to 2016, records show chart breaking numbers for citation in research submitted. This is most likely indicated of a rise in the standard in quality or a phenomenon that still remains unexplained. Numbers do not lie. They only try to explain the phenomenons that we see happening in our reality. And, in the case of Oncotarget, the reality base is long and wide ranged like the various subjects that are affected by oncology.

So, can these numbers really be explained in simple words without some type of facts or figures involved? Once you have laid eyes on the work product coming from the organization by Mikhail Blagosklonny, the answer becomes clear as a bell ringing on a sunny day. Yes. The fact finders on these projects are serious about their work product and nothing is ever overlooked. Things are perfect down to the 97 percentile. Some of these studies include subject matter that is not so complicated such as photodynamic therapy on some of fibrosis patients especially where Xeroderma pigmentosum and for Goblin Goltz syndrome.

Other studies show near miraculous results as in tumor suppression in the cases of metastasis.What this basically looks like is a spike from 4.8 citations for document to 8.4 over the course of 2011 to 2016. Not to mention that over the same course of time total citations for the organization as a whole jumped from 0 to 20,000 while self citations remained incredibly low points to the due diligence of the work submitted. Which coincides nicely with the international collaboration stats which went from 22.5 in 2011 to 37.5 by 2014 and just above 30 in 2016. The number of citable and cited documents climb steadily over the same course of time 2011-2016 from 0 to 5000 easily.

Using Oncotarget to Educate The Public on the Development Cancer Research

According to statistics by world health organization, cancer cases are increasing by the day. Provision of information on better cancer management practices comes in handy for cancer patients and physicians treating the ailment. Oncotarget is a reputable medical journal that has the editorial inputs of the scientists, Mikhail Blagosklonny of and Andrew V. Gudkov, who both work at Roswell Park Cancer Institute. The two medical experts research on the development of cancer treatments and publish their findings on Oncotarget.

The peer-reviewed journal provides information on pathological causes of all types of cancer. The journal also covers possible treatment options available for patients and practitioners. More to this, it offers information on the standards that must be observed to enhance the health status of patients, with intent to improve their quality of life. Download output styles at

Varying treatment and management options are available considering research indicates that there are different causes of cancer in different persons. The journal explores all the available options to ensure patients and care providers get fully informed on these options. Furthermore, the journal explores the possible outcomes to expect from applying each of the suggested methods.

Research on treatment and care for cancer patients improves rapidly. Oncotarget’s journal explores these emerging treatment options. Information provided widens the scope of choices available to patients by offering regular updates on upgraded treatment options available for patients and healthcare providers. Factual and meaningful information comes in handy for successful treatment. In addition to Mikhail’s and Andrew’s findings, the journal puts out articles from only reliable sources in the medical world. Each of the items posted is intensely scrutinized to ascertain its authenticity by a dedicated team of editors. Providing factual information is a measure to ensure the information given is adequate and resourceful to readers.

Recently, Oncotarget has released publications on subjects beyond oncology such as cardiology, metabolism, cell biology with the intention of providing the medical community and patients with a better understanding and the functionality of the human body in regards to these ailments. The journal provides information free of cost and has the backing of medical professionals such as Zeng Yixin of South China and Garry Melino of Rome. Learn more about Oncotarget at

The Research of Mikhail Blagosklonny

Mikhail Blagosklonny is an influential research, professor, as well as individual who wants to make the world a better place with the discovery that he has already made and will continue to make within the areas of study such as cancer as well as aging. Mikhail Blagosklonny has always been fascinated by both areas of study and wants to provide his own input in order to make further discoveries that will help cancer patients. As a professional within the study of medicine, Mikhail Blagosklonny wants to help others and to improve any experience with cancer and to make the process of aging less detrimental to the health of humans. Mikhail Blagosklonny has conducted decades of study and hopes that his research will inspire others to pick up where he will leave off in order to help individuals all over the world. Mikhail Blagosklonny hopes to one day eliminate cancer through simple treatments on in order to eliminate the excruciating and expensive process that cancer consists of in present day.

Mikhail Blagosklonny is an expert within the field of medicine and is specifically an expert when it comes to aging as well as cancer. The goal of Mikhail Blagosklonny is to find a way to destroy the cancerous cells within the body in an efficient manner that will not destroy the normal cells in the process. The destruction of normal cells through treatment such as radiation and chemotherapy makes the recovery of cancer even harder and weakens the body for the rest of the patient’s life.

Mikhail Blagosklonny is a professor of medicine and was an associate professor at the New York Medical College up until 2009 when he was appointed as the professor of oncology at the Roswell Park Cancer Institute that conducts research to improve the cancer treatment process on Mikhail Blagosklonny’s favorite aspect of his job is the fact that he is able to take students under his wing and is able to inspire them with his research within the field of oncology. Mikhail Blagosklonny hopes that some of his students will continue his research in the future in order to help others.